<DOC>
	<DOCNO>NCT00418860</DOCNO>
	<brief_summary>The purpose study determine whether dual antiplatelet therapy ( aspirin clopidogrel ) 3 month coronary implantation zotarolimus-eluting stent safe term death , myocardial infarction , stent thrombosis .</brief_summary>
	<brief_title>The Optimal Duration Dual Antiplatelet Therapy After Implantation Endeavor Stent</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>Patients clinically significant de novo coronary artery disease Stenting EndeavorÂ® stents The sum stent length le 60 mm one lesion . The sum stent length multiple lesion matter . Cardiogenic shock STelevation myocardial infarction within 48 hour symptom onset Prior implantation drugeluting stent Left ventricular dysfunction ( echocardiographic leave ventricular ejection fraction &lt; 25 % ) Stenting branch bifurcation lesion Left main trunk lesion Graft vessel Patients receive clopidogrel due condition Patients receive warfarin , cilostazol antiplatelet therapy Patient chronic renal failure ( SCr &gt; 2.0 mg/dl ) Hypersensitivity clopidogrel aspirin Expectant survival less 1 year Women plan become pregnant Patients bleed diathesis ( coagulopathy , thrombocytopenia platelet dysfunction , Gastrointestinal genitourinary bleeding within prior 3 month ) Patients actively participate another drug device investigational study , complete primary endpoint followup period .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Angioplasty , Transluminal , Percutaneous Coronary</keyword>
	<keyword>Stent thrombosis</keyword>
	<keyword>Zotarolimus-eluting stent</keyword>
</DOC>